Spots Global Cancer Trial Database for Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Official Title: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Study ID: NCT02122822
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This trial is studying the safety and effectiveness of autologous gp96 treatment of glioblastoma and to see how well it works in treating patients with newly diagnosed supratentoria glioma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, , China
Contact Details
Name: Zhixian Gao, Doctor
Affiliation: Beijing Tiantan Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
